

BIOLIDICS LIMITED
(Company Registration Number 200913076M)
(Incorporated in the Republic of Singapore)

**ACQUISITION OF THE ENTIRE ISSUED AND PAID-UP SHARE CAPITAL OF BIOMEDICS
LABORATORY PTE. LTD. –**

**ALLOTMENT AND ISSUANCE OF 37,500,000 NEW ORDINARY SHARES IN THE CAPITAL OF
BIOLIDICS LIMITED**

The board of directors (the “**Board**”) of Biolidics Limited (the “**Company**”) refers to the Company’s announcements dated 28 February 2023 and 16 March 2023 (“**Announcements**”) in relation to the entry into of a partial settlement deed with Clearbridge BSA Pte. Ltd. (“**CBSA**”) on the partial settlement of the deferred consideration owing by the Company to CBSA (“**Deferred Consideration**”) in connection with the acquisition of the entire issued and paid-up share capital of Biomedics Laboratory Pte. Ltd..

Capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Announcements.

The Board wishes to announce that the Company has today, allotted and issued the 37,500,000 Consideration Shares to CBSA. Following the completion of the payment of the Cash Settlement Sum and the issuance of the Consideration Shares to CBSA, the balance sum of the Deferred Consideration, being S\$2,138,750, shall be payable by the Company to CBSA no later than 25 November 2023 by way of bank transfer of immediately available funds to an account designated by CBSA.

The Consideration Shares shall rank *pari passu* in all respects with the existing issued Shares and are expected to be listed and quoted on Catalist on or about 22 March 2023.

Following the allotment and issuance of the 37,500,000 Consideration Shares, the total number of Shares has increased from 521,626,605 Shares to 559,126,605 Shares.

BY ORDER OF THE BOARD

Song Tang Yih

Executive Director and Chief Executive Officer

20 March 2023

*This announcement has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “**Sponsor**”), for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lim Hoon Khia, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.